Last edition
News about
AskBio Completes Enrollment for Phase 2 Gene Therapy Trial Targeting Heart Failure
The GenePHIT study evaluating investigational therapy AB-1002 for heart failure with reduced ejection fraction has fully enrolled 173 patients, with initial results expected in early 2027.
Samsung Biologics Expands into US with GSK Facility Acquisition in Maryland
Samsung Biologics has completed the acquisition of a biologics manufacturing facility in Rockville, Maryland from GSK, marking its first manufacturing presence in the United States.
Gilead Extends Tender Offer to Acquire Arcellx
Gilead extends tender offer to acquire Arcellx until April 24, 2026, providing additional time for shareholders to participate in the proposed acquisition.
Glenmark Takes Full Control of Ryaltris in US, Bets on Direct Market Strategy
Glenmark Pharmaceuticals has announced a strategic shift to directly commercialise and distribute its nasal spray Ryaltris in the United States, moving away from its earlier partner-led model.
BioXcel Therapeutics Announces FDA Acceptance of Supplemental NDA for IGALMI
BioXcel Therapeutics receives FDA acceptance for supplemental NDA of IGALMI, targeting acute agitation in bipolar disorder and schizophrenia for potential at-home treatment use.
Seasonal Flu Vaccines to Target Three Strains in 2026-27: EMA Guidance
The European Medicines Agency (EMA) has issued its recommendations for the influenza virus strains to be included in vaccines for the 2026–2027 seasonal flu campaign.
Alltrna Receives Approval to Begin First-in-Human Trial of tRNA Therapeutic AP003
Alltrna initiates first-in-human trial of engineered tRNA therapy AP003 in Australia, marking a breakthrough in genetic disease treatment.
GHIT Fund and TSRI Sign MoU to Boost Global Infectious Disease R&D Collaboration
The partnership aims to co-fund research on malaria, tuberculosis, and neglected tropical diseases while strengthening innovation ecosystems and capacity building across Thailand and Japan.
NJ Bio, Aji Bio-Pharma Partner to Expand Access to AJICAP Platform
The collaboration between NJ Bio and Bio Pharma aims to accelerate development of next-generation antibody–drug conjugates through advanced site-specific conjugation technology.
Abbisko's Irpagratinib Secures EMA Orphan Drug Tag for Liver Cancer
European regulator grants rare disease designation to FGFR4 inhibitor, boosting its clinical development and commercial prospects in hepatocellular carcinoma.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy